Veeva Systems
Sorbet currently classifies Veeva Systems as the challenger in its Regulated & federal bucket. The detailed selection note is not yet available.
Strengthening
Based on 2 material signals in the last 30 days: 2 positive, 0 negative.
Evidence summary, not a buy / sell rating
Latest approved decision: hold · 2026-08-29
The role and pillars explain what job this holding has inside the System-of-Record basket—not whether it suits an individual investor.
Veeva Systems earns its place in the regulated and federal bucket by owning the life-sciences industry's most consequential structured records: clinical trial data, regulatory submissions, quality events, and validated document histories that must satisfy FDA 21 CFR Part 11 and EMA Annex 11 by law. Those records are durable by regulatory construction — they cannot be deleted, must carry complete audit trails, and require typed ownership at every state transition, satisfying P1 (records, not content), P2 (state machine, not labels), and P3 (ownership, not implication) directly. The Vault platform's submission dossiers, quality management workflows, and clinical data objects are precisely the kind of named, versioned, permissioned state that agents need to perform real regulated work — document comparison, deviation triage, change-control routing — without hallucinating provenance. As the challenger in this bucket, Veeva occupies the position of a deep-vertical specialist whose moat is narrower than a hyperscaler's but structurally harder to dislodge: a competitor must simultaneously replicate the record model, the validation posture, and the regulatory trust that pharma quality teams have already staked their submissions on. That combination of regulatory lock-in and rich structured substrate makes Veeva a high-conviction bet on the thesis claim that the boring, compliance-heavy tools are exactly where agentic work will first be trusted at scale.
A paper position testing whether a credible alternative can take share or express the thesis more efficiently than the bucket leader.
The thesis properties this holding is selected to test. These labels are portfolio classifications, not standalone proof.
Durable records
Explicit state machine
Typed ownership
The thesis for Veeva breaks structurally — not merely underperforms — if one or more of the following concrete conditions materialise. First, if a foundation-model provider or a hyperscaler (most plausibly Microsoft via Azure Health or AWS via HealthLake) ships a validated, 21 CFR Part 11-compliant vault and audit-trail layer that life-sciences customers actually re-platform onto, the regulatory moat that makes Veeva a records substrate rather than a replaceable application collapses; the signal to watch is a named pharma Top-20 customer publicly migrating clinical or regulatory content out of Vault in favour of a cloud-native alternative. Second, if Veeva fails to convert its existing record ownership in Vault into a monetisable agent SKU — meaning agent-consumption ARR remains immaterial through fiscal 2028 while NOW or CRM demonstrate the monetisation playbook works in adjacent regulated verticals — that is an ARR-structure falsifier under the same invalidator the thesis names for all SoR incumbents. Third, open-source or low-cost validated-cloud clones (watch Alkymi, or a potential AWS-sponsored open validation framework) gaining a named Tier-1 CRO or sponsor reference would signal pricing-power erosion on P1 and P3 simultaneously, which under the two-pillar rule triggers a trim review. Underperformance in a risk-off quarter is not falsification; the structural break is loss of the regulatory record as the irreplaceable substrate.
Daily closes are shown for context. Reference levels are deterministic outputs of Sorbet's published ATR method, not analyst targets or advice.
2025-07-28 → 2026-08-31
$285.69
Short-term levels use 14d ATR and the 200d average. The 3y projection compounds the current revenue-growth rate with no multiple expansion. Missing inputs stay blank.
Revenue growth + FCF yield, not the conventional FCF-margin formulation. Visible for judgment, but not wired into selection.
Price is above both the 50d and 200d averages, with the faster average leading.
| Quarter | Revenue YoY | Gross margin | FCF margin | Operating margin |
|---|---|---|---|---|
| 2026-01-31 | 17.58% | 74.46% | 11.94% | 29.41% |
| 2025-10-31 | 13.31% | 75.41% | 22.55% | 29.69% |
| 2025-07-31 | 14.52% | 75.26% | 29.42% | 24.83% |
| 2025-04-30 | 15.42% | 77.10% | 1.15% | 30.79% |
| 2025-01-31 | 12.30% | 74.89% | 8.99% | 26.14% |
| 2024-10-31 | 12.58% | 75.06% | 22.86% | 25.94% |
Veeva's trajectory runs through deepening its Vault platform into a genuine agent substrate for regulated life-sciences workflows — clinical trial records, regulatory submissions, quality events, and pharmacovigilance cases each carry the durable-record and named-state-transition structure the thesis prizes, and the question is whether Veeva extends that into machine-readable, machine-writable surfaces at pace. The immediate execution imperative is shipping stable API and MCP-class access across Vault so that agents can read every audit trail, ownership field, and state transition without human intermediation — P4 and P5 remain unproven at the depth that would fully qualify Veeva as agent infrastructure rather than agent-adjacent storage. Vault CRM's displacement of Salesforce inside the life-sciences vertical is a compounding signal: customers consolidating onto a single regulated SoR reduce the translation friction that degrades agent effectiveness, and each consolidation win enlarges the queryable history an agent can draw on. What is still missing is a credible agent SKU — Veeva has not yet demonstrated monetisation of the substrate in the way ServiceNow or Salesforce have with explicit agent-layer pricing, and until consumption-based agent revenue appears in the model, the challenger positioning reflects potential rather than confirmed execution.
Teva Pharmaceuticals Commits to Veeva Vault CRM
Teva's global commitment to Veeva Vault CRM reinforces Veeva's role as a durable records platform (customer accounts, lifecycle stages) in the life sciences vertical, directly supporting the 'Records, not content' pillar (P1).
Source: Yahoo
Veeva Announces Falcon, an Agentic Platform and Standard Agents to Deliver Agentic Labor in Drug Development
Veeva's Falcon platform explicitly builds agentic labor on top of its existing durable records (clinical, regulatory, safety documents), directly supporting the thesis that record-rich platforms become agent infrastructure.
Source: Yahoo
positive signal but thin coverage (only P1) — hold for confirmation.
Earnings in 1 day(s). Defer trim/add proposals through the print.
Missing data. No owner-reviewed NRR disclosure is available. Unreviewed AI extraction is never shown publicly.